Phathom Pharmaceuticals, Inc. has announced its financial results for the third quarter of 2026, showcasing a remarkable 71% increase in net revenues compared to the same period last year. This growth is largely attributed to the successful commercialization of VOQUEZNA, a treatment for gastroesophageal reflux disease (GERD). The company's ability to generate positive operating cash flow for the second consecutive quarter underscores its financial transformation and operational efficiency.

On October 29, 2026, Phathom Pharmaceuticals issued a press release detailing its financial performance for the quarter ended September 30, 2026. The announcement is significant for the company as it reflects a strong upward trajectory in both revenue and market presence. With over 2 million prescriptions filled for VOQUEZNA, Phathom is solidifying its position in the pharmaceutical preparations sector, which encompasses a wide range of companies focused on developing and marketing medicinal products.

Background

Phathom Pharmaceuticals, Inc. (CIK: 0001783183) operates in the pharmaceutical preparations industry (SIC: 2834) and is listed on the Nasdaq under the ticker symbol PHAT. The company is based in Florham Park, New Jersey, and focuses on developing novel treatments for gastrointestinal diseases. Recent filings include a 10-Q on October 29, 2026, and an 8-K on the same day, reflecting ongoing financial reporting and compliance.

What the Filing Says

The filing reveals that Phathom's Q3 2026 net revenues reached $84.7 million, marking a 71% increase compared to Q3 2025 and a 14% rise from Q2 2026. The company reported that it generated positive operating cash flow for the second consecutive quarter, reaffirming its full-year financial guidance.

Impact

This financial performance may affect various stakeholders, including investors, healthcare providers, and patients. Investors may view the results as a positive indicator of the company's growth potential, while healthcare providers may be encouraged to prescribe VOQUEZNA more frequently given its increasing market presence. Patients could benefit from improved access to the medication, particularly with new initiatives aimed at reducing out-of-pocket costs.

What's Next

Phathom Pharmaceuticals is expected to continue its momentum with the ongoing promotion of VOQUEZNA and its clinical trials. The filing does not specify what happens next, but the company has announced a conference call and webcast scheduled for October 29, 2026, at 8:00 a.m. EDT, where further updates may be provided.